Anti-human PD-L1 humanized monoclonal antibody and application thereof
US11155626B2 · kind B2 · utility
1Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2016 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Feb 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the biomedicine field, in particular to an anti-human PD-L1 humanized monoclonal antibody and its applications. The invention obtains an anti-human PD-L1 humanized monoclonal antibody with good specificity, high affinity and stability by screening, and the antibody can specifically bind to human PD-L1 instead of binding to members of B7 family, and it can bind to active T-cells to strengthen the activation of T-cells, so it can significantly inhibit the growth of tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.